Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients

Shoji Nagao, Naoki Okimoto, Atsushi Hongo, Yasushi Mizutani, Junichi Kodama, Mitsuo Yoshinouchi, Yuji Hiramatsu, Takafumi Kudo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To evaluate the validity of administration of paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients with gynecologic cancer, we explored the efficacy and safety of these regimens. From October 1, 1998 to September 30, 2001, we administered paclitaxel and carboplatin with or without THP-ADR pursuant to the chart we prepared originally as first line chemotherapy in patients with gynecologic cancer. Eleven elderly patients (age > 70 years) and 62 younger patients (age <70 years) were entered into the present study. Paclitaxel was administered as a 3-hour intravenous (i.v.) infusion at dosages of 135 to 180 mg/m2 immediately followed by carboplatin over 60 minutes at dosages of area under the curve (AUC) 3 to 5, administered intravenously or intraperitoneally. We observed grade 3/4 anemia more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin without THP-ADR (9% v.s. 47%, p <0.0001). Grade 3/4 anemia (10% v.s. 22%, p = 0.02) and grade 3/4 thrombocytopenia (7% v.s. 22%, p = 0.007), febrile neutropenia (14% v.s. 44%, p = 0.02) also occurred more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin with THP-ADR. The overall response rates were equivalent among elderly and younger patients (69% and 78%), respectively. The regimen consisting of paclitaxel and carboplatin without THP-ADR was applied safely to elderly patients.

Original languageEnglish
Pages (from-to)243-249
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume30
Issue number2
Publication statusPublished - Feb 2003

Fingerprint

Carboplatin
Paclitaxel
Drug Therapy
Anemia
Febrile Neutropenia
pirarubicin
Intravenous Infusions
Area Under Curve
Neoplasms
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Nagao, S., Okimoto, N., Hongo, A., Mizutani, Y., Kodama, J., Yoshinouchi, M., ... Kudo, T. (2003). Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients. Gan to kagaku ryoho. Cancer & chemotherapy, 30(2), 243-249.

Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients. / Nagao, Shoji; Okimoto, Naoki; Hongo, Atsushi; Mizutani, Yasushi; Kodama, Junichi; Yoshinouchi, Mitsuo; Hiramatsu, Yuji; Kudo, Takafumi.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 30, No. 2, 02.2003, p. 243-249.

Research output: Contribution to journalArticle

Nagao, S, Okimoto, N, Hongo, A, Mizutani, Y, Kodama, J, Yoshinouchi, M, Hiramatsu, Y & Kudo, T 2003, 'Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 30, no. 2, pp. 243-249.
Nagao, Shoji ; Okimoto, Naoki ; Hongo, Atsushi ; Mizutani, Yasushi ; Kodama, Junichi ; Yoshinouchi, Mitsuo ; Hiramatsu, Yuji ; Kudo, Takafumi. / Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2003 ; Vol. 30, No. 2. pp. 243-249.
@article{3bb4116c47b749689282ab73be22f7ae,
title = "Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients",
abstract = "To evaluate the validity of administration of paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients with gynecologic cancer, we explored the efficacy and safety of these regimens. From October 1, 1998 to September 30, 2001, we administered paclitaxel and carboplatin with or without THP-ADR pursuant to the chart we prepared originally as first line chemotherapy in patients with gynecologic cancer. Eleven elderly patients (age > 70 years) and 62 younger patients (age <70 years) were entered into the present study. Paclitaxel was administered as a 3-hour intravenous (i.v.) infusion at dosages of 135 to 180 mg/m2 immediately followed by carboplatin over 60 minutes at dosages of area under the curve (AUC) 3 to 5, administered intravenously or intraperitoneally. We observed grade 3/4 anemia more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin without THP-ADR (9{\%} v.s. 47{\%}, p <0.0001). Grade 3/4 anemia (10{\%} v.s. 22{\%}, p = 0.02) and grade 3/4 thrombocytopenia (7{\%} v.s. 22{\%}, p = 0.007), febrile neutropenia (14{\%} v.s. 44{\%}, p = 0.02) also occurred more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin with THP-ADR. The overall response rates were equivalent among elderly and younger patients (69{\%} and 78{\%}), respectively. The regimen consisting of paclitaxel and carboplatin without THP-ADR was applied safely to elderly patients.",
author = "Shoji Nagao and Naoki Okimoto and Atsushi Hongo and Yasushi Mizutani and Junichi Kodama and Mitsuo Yoshinouchi and Yuji Hiramatsu and Takafumi Kudo",
year = "2003",
month = "2",
language = "English",
volume = "30",
pages = "243--249",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients

AU - Nagao, Shoji

AU - Okimoto, Naoki

AU - Hongo, Atsushi

AU - Mizutani, Yasushi

AU - Kodama, Junichi

AU - Yoshinouchi, Mitsuo

AU - Hiramatsu, Yuji

AU - Kudo, Takafumi

PY - 2003/2

Y1 - 2003/2

N2 - To evaluate the validity of administration of paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients with gynecologic cancer, we explored the efficacy and safety of these regimens. From October 1, 1998 to September 30, 2001, we administered paclitaxel and carboplatin with or without THP-ADR pursuant to the chart we prepared originally as first line chemotherapy in patients with gynecologic cancer. Eleven elderly patients (age > 70 years) and 62 younger patients (age <70 years) were entered into the present study. Paclitaxel was administered as a 3-hour intravenous (i.v.) infusion at dosages of 135 to 180 mg/m2 immediately followed by carboplatin over 60 minutes at dosages of area under the curve (AUC) 3 to 5, administered intravenously or intraperitoneally. We observed grade 3/4 anemia more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin without THP-ADR (9% v.s. 47%, p <0.0001). Grade 3/4 anemia (10% v.s. 22%, p = 0.02) and grade 3/4 thrombocytopenia (7% v.s. 22%, p = 0.007), febrile neutropenia (14% v.s. 44%, p = 0.02) also occurred more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin with THP-ADR. The overall response rates were equivalent among elderly and younger patients (69% and 78%), respectively. The regimen consisting of paclitaxel and carboplatin without THP-ADR was applied safely to elderly patients.

AB - To evaluate the validity of administration of paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients with gynecologic cancer, we explored the efficacy and safety of these regimens. From October 1, 1998 to September 30, 2001, we administered paclitaxel and carboplatin with or without THP-ADR pursuant to the chart we prepared originally as first line chemotherapy in patients with gynecologic cancer. Eleven elderly patients (age > 70 years) and 62 younger patients (age <70 years) were entered into the present study. Paclitaxel was administered as a 3-hour intravenous (i.v.) infusion at dosages of 135 to 180 mg/m2 immediately followed by carboplatin over 60 minutes at dosages of area under the curve (AUC) 3 to 5, administered intravenously or intraperitoneally. We observed grade 3/4 anemia more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin without THP-ADR (9% v.s. 47%, p <0.0001). Grade 3/4 anemia (10% v.s. 22%, p = 0.02) and grade 3/4 thrombocytopenia (7% v.s. 22%, p = 0.007), febrile neutropenia (14% v.s. 44%, p = 0.02) also occurred more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin with THP-ADR. The overall response rates were equivalent among elderly and younger patients (69% and 78%), respectively. The regimen consisting of paclitaxel and carboplatin without THP-ADR was applied safely to elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=0037317931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037317931&partnerID=8YFLogxK

M3 - Article

C2 - 12610873

AN - SCOPUS:0037317931

VL - 30

SP - 243

EP - 249

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 2

ER -